BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 38555405)

  • 21. Identification of MLL-fusion/MYC⊣miR-26⊣TET1 signaling circuit in MLL-rearranged leukemia.
    Huang H; Jiang X; Wang J; Li Y; Song CX; Chen P; Li S; Gurbuxani S; Arnovitz S; Wang Y; Weng H; Neilly MB; He C; Li Z; Chen J
    Cancer Lett; 2016 Mar; 372(2):157-65. PubMed ID: 26791235
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tet1 is not required for myeloid leukemogenesis by MLL-ENL in novel mouse models.
    Ono R; Masuya M; Inoue N; Shinmei M; Ishii S; Maegawa Y; Maharjan BD; Katayama N; Nosaka T
    PLoS One; 2021; 16(3):e0248425. PubMed ID: 33705482
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HBO1-MLL interaction promotes AF4/ENL/P-TEFb-mediated leukemogenesis.
    Takahashi S; Kanai A; Okuda H; Miyamoto R; Komata Y; Kawamura T; Matsui H; Inaba T; Takaori-Kondo A; Yokoyama A
    Elife; 2021 Aug; 10():. PubMed ID: 34431785
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MLL fusion proteins preferentially regulate a subset of wild-type MLL target genes in the leukemic genome.
    Wang QF; Wu G; Mi S; He F; Wu J; Dong J; Luo RT; Mattison R; Kaberlein JJ; Prabhakar S; Ji H; Thirman MJ
    Blood; 2011 Jun; 117(25):6895-905. PubMed ID: 21518926
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The developmental stage of the hematopoietic niche regulates lineage in
    Rowe RG; Lummertz da Rocha E; Sousa P; Missios P; Morse M; Marion W; Yermalovich A; Barragan J; Mathieu R; Jha DK; Fleming MD; North TE; Daley GQ
    J Exp Med; 2019 Mar; 216(3):527-538. PubMed ID: 30728174
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Murine Retrovirally-Transduced Bone Marrow Engraftment Models of MLL-Fusion-Driven Acute Myelogenous Leukemias (AML).
    Stubbs MC; Krivtsov AV
    Curr Protoc Pharmacol; 2017 Sep; 78():14.42.1-14.42.19. PubMed ID: 28892146
    [TBL] [Abstract][Full Text] [Related]  

  • 27. When epigenetics kills: MLL fusion proteins in leukemia.
    Slany RK
    Hematol Oncol; 2005 Mar; 23(1):1-9. PubMed ID: 16118769
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential regulation of the c-Myc/Lin28 axis discriminates subclasses of rearranged MLL leukemia.
    Chen L; Sun Y; Wang J; Jiang H; Muntean AG
    Oncotarget; 2016 May; 7(18):25208-23. PubMed ID: 27007052
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia.
    Chen CW; Koche RP; Sinha AU; Deshpande AJ; Zhu N; Eng R; Doench JG; Xu H; Chu SH; Qi J; Wang X; Delaney C; Bernt KM; Root DE; Hahn WC; Bradner JE; Armstrong SA
    Nat Med; 2015 Apr; 21(4):335-43. PubMed ID: 25822366
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia.
    Baker A; Gregory GP; Verbrugge I; Kats L; Hilton JJ; Vidacs E; Lee EM; Lock RB; Zuber J; Shortt J; Johnstone RW
    Cancer Res; 2016 Mar; 76(5):1158-69. PubMed ID: 26627013
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Uncovering NOTCH1 as a Promising Target in the Treatment of
    Fischer J; Erkner E; Fitzel R; Radszuweit P; Keppeler H; Korkmaz F; Roti G; Lengerke C; Schneidawind D; Schneidawind C
    Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833915
    [No Abstract]   [Full Text] [Related]  

  • 32. SIRT2 regulates proliferation and chemotherapy response of MLL-ENL-driven acute myeloid leukemia.
    Hao C; Shao X; Song J; Peng M; Lao Y; Mack R; Zhang L; Wei W; Liu N; Wang T; Wu Y; Feng L; Yin L; Wang S; Sun X; Chen S; Zhang J; Li B
    Biochem Biophys Res Commun; 2022 Mar; 596():36-42. PubMed ID: 35108652
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
    Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
    J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The efficiency of murine MLL-ENL-driven leukemia initiation changes with age and peaks during neonatal development.
    Okeyo-Owuor T; Li Y; Patel RM; Yang W; Casey EB; Cluster AS; Porter SN; Bryder D; Magee JA
    Blood Adv; 2019 Aug; 3(15):2388-2399. PubMed ID: 31405949
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Initiation of MLL-rearranged AML is dependent on C/EBPα.
    Ohlsson E; Hasemann MS; Willer A; Lauridsen FK; Rapin N; Jendholm J; Porse BT
    J Exp Med; 2014 Jan; 211(1):5-13. PubMed ID: 24367003
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Two decades of leukemia oncoprotein epistasis: the MLL1 paradigm for epigenetic deregulation in leukemia.
    Li BE; Ernst P
    Exp Hematol; 2014 Dec; 42(12):995-1012. PubMed ID: 25264566
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Learning from mouse models of MLL fusion gene-driven acute leukemia.
    Schwaller J
    Biochim Biophys Acta Gene Regul Mech; 2020 Aug; 1863(8):194550. PubMed ID: 32320749
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The MLL recombinome of acute leukemias in 2013.
    Meyer C; Hofmann J; Burmeister T; Gröger D; Park TS; Emerenciano M; Pombo de Oliveira M; Renneville A; Villarese P; Macintyre E; Cavé H; Clappier E; Mass-Malo K; Zuna J; Trka J; De Braekeleer E; De Braekeleer M; Oh SH; Tsaur G; Fechina L; van der Velden VH; van Dongen JJ; Delabesse E; Binato R; Silva ML; Kustanovich A; Aleinikova O; Harris MH; Lund-Aho T; Juvonen V; Heidenreich O; Vormoor J; Choi WW; Jarosova M; Kolenova A; Bueno C; Menendez P; Wehner S; Eckert C; Talmant P; Tondeur S; Lippert E; Launay E; Henry C; Ballerini P; Lapillone H; Callanan MB; Cayuela JM; Herbaux C; Cazzaniga G; Kakadiya PM; Bohlander S; Ahlmann M; Choi JR; Gameiro P; Lee DS; Krauter J; Cornillet-Lefebvre P; Te Kronnie G; Schäfer BW; Kubetzko S; Alonso CN; zur Stadt U; Sutton R; Venn NC; Izraeli S; Trakhtenbrot L; Madsen HO; Archer P; Hancock J; Cerveira N; Teixeira MR; Lo Nigro L; Möricke A; Stanulla M; Schrappe M; Sedék L; Szczepański T; Zwaan CM; Coenen EA; van den Heuvel-Eibrink MM; Strehl S; Dworzak M; Panzer-Grümayer R; Dingermann T; Klingebiel T; Marschalek R
    Leukemia; 2013 Nov; 27(11):2165-76. PubMed ID: 23628958
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dysregulation of the DNA Damage Response and KMT2A Rearrangement in Fetal Liver Hematopoietic Cells.
    Nanya M; Sato M; Tanimoto K; Tozuka M; Mizutani S; Takagi M
    PLoS One; 2015; 10(12):e0144540. PubMed ID: 26657054
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.
    Chen WL; Li DD; Chen X; Wang YZ; Xu JJ; Jiang ZY; You QD; Guo XK
    Eur J Med Chem; 2020 Feb; 188():112027. PubMed ID: 31923859
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.